AGAP2 and non-small cell lung carcinoma: Thus, these data suggest that exosomal lncRNAs TBILA and AGAP2-AS1 might be promising biomarker for the diagnosis of patients with NSCLC, and the combination of two exosomal lncRNAs and Cyfra21-1 might be a good diagnostic panel for NSCLC.